Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Teva Pharmaceuticals International Gmbh patents


Recent patent applications related to Teva Pharmaceuticals International Gmbh. Teva Pharmaceuticals International Gmbh is listed as an Agent/Assignee. Note: Teva Pharmaceuticals International Gmbh may have other listings under different names/spellings. We're not affiliated with Teva Pharmaceuticals International Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Teva Pharmaceuticals International Gmbh-related inventors


 new patent  Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

Solid state forms of trisodium valsartan: sacubitril

Solid state forms of trisodium vaisartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.. . ... Teva Pharmaceuticals International Gmbh

Treating refractory migraine

Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the cgrp pathway. Compositions for use in the disclosed methods are also provided. ... Teva Pharmaceuticals International Gmbh

Teva Pharmaceuticals International Gmbh

. . ... Teva Pharmaceuticals International Gmbh

Use of pridopidine for treating functional decline

This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.. . ... Teva Pharmaceuticals International Gmbh

Solid state forms of spiro-oxindole compounds

The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (r) enantiomer, pharmaceutical compositions comprising the solid state forms and processes for preparing the solid state forms and the pharmaceutical compositions.. . ... Teva Pharmaceuticals International Gmbh

Asymmetric synthesis of funapide

This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.. . ... Teva Pharmaceuticals International Gmbh

Medical device packaging

Packaging (4) for an injection device (6, 92), the packaging comprising: a compartment (32) forming a recess configured to house the injection device therein, the compartment extending in a longitudinal direction, a depth direction, and having a variable lateral width to accommodate the injection device; a first sidewall (54) extending in the depth direction and longitudinal direction contiguous a portion of the compartment; and a lip (56) adjoining the sidewall and said portion of the compartment, wherein the first sidewall is arranged within a field of width of the compartment, the lip arranged at a height (h) from a base of said portion of the compartment, such that the lip and first sidewall prevent user gripping of a housed injection device at said portion of the compartment.. . ... Teva Pharmaceuticals International Gmbh

Methods of treating chronic pain

The invention relates to an anti-cgrp antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-cgrp antibody.. . ... Teva Pharmaceuticals International Gmbh

Pharmaceutical compositions for combination therapy

This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (vmat) known as tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with huntington's disease, gilles de la tourette's syndrome, or tardive dyskinesia.. ... Teva Pharmaceuticals International Gmbh

Antagonist antibodies directed against calcitonin gene- related peptide

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

Antagonist antibodies directed against calcitonin gene- related peptide

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

Antagonist antibodies directed against calcitonin gene- related peptide

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

Antagonist antibodies directed against calcitonin gene- related peptide

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

06/15/17 / #20170165381

Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson's disease

The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-o-methyltransferase (comt) inhibitors.. . ... Teva Pharmaceuticals International Gmbh

05/04/17 / #20170120047

Iontophoretic drug delivery method

The present invention relates generally to iontophoretic drug delivery systems for transdermal delivery of therapeutic agents and, more particularly, to packaging such systems for long shelf life and easy assembly for use. The system package includes an iontophoretic skin worn patch component that accommodates a power source, electronics, electrodes and a drug pack component that carries a therapeutic agent which is contained as a separate sealed component. ... Teva Pharmaceuticals International Gmbh

04/27/17 / #20170112779

Polyamine enhanced formulations for triptan compound iontophoresis

A patch and compositions for iontophoresis of triptan compounds are described.. . ... Teva Pharmaceuticals International Gmbh

03/30/17 / #20170088612

Preventing, treating, and reducing (persistent) post-traumatic headache

Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the cgrp pathway. Compositions for use in the disclosed methods are also provided. ... Teva Pharmaceuticals International Gmbh

03/23/17 / #20170081395

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described.. ... Teva Pharmaceuticals International Gmbh

03/23/17 / #20170079985

Sustained release olanzapine formulations

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.. ... Teva Pharmaceuticals International Gmbh

01/26/17 / #20170022158

Process for preparing pridopidine

This invention provides a pridopidine base in a solid form, a method of preparing the solid pridopidine base, and a composition comprising the pridopidine base including a pharmaceutical composition.. . ... Teva Pharmaceuticals International Gmbh

01/26/17 / #20170020854

Pridopidine base formulations and their use

This invention provides modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine base, and at least one pharmaceutically acceptable rate controlling excipient.. . ... Teva Pharmaceuticals International Gmbh

01/19/17 / #20170015696

Solid state forms of sofosbuvir

The present disclosure encompasses solid state forms of sofosbuvir and pharmaceutical compositions thereof.. . ... Teva Pharmaceuticals International Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Teva Pharmaceuticals International Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Teva Pharmaceuticals International Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###